ES2454773T3 - Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN - Google Patents

Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN Download PDF

Info

Publication number
ES2454773T3
ES2454773T3 ES08838119.9T ES08838119T ES2454773T3 ES 2454773 T3 ES2454773 T3 ES 2454773T3 ES 08838119 T ES08838119 T ES 08838119T ES 2454773 T3 ES2454773 T3 ES 2454773T3
Authority
ES
Spain
Prior art keywords
amino acid
polypeptide
seq
terminal end
aligned
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08838119.9T
Other languages
English (en)
Spanish (es)
Inventor
Stephen Cusack
Delphine Guilligay
Darren Hart
Franck Tarendeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Europaisches Laboratorium fuer Molekularbiologie EMBL
Original Assignee
Europaisches Laboratorium fuer Molekularbiologie EMBL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Europaisches Laboratorium fuer Molekularbiologie EMBL filed Critical Europaisches Laboratorium fuer Molekularbiologie EMBL
Application granted granted Critical
Publication of ES2454773T3 publication Critical patent/ES2454773T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D1/00Rigid or semi-rigid containers having bodies formed in one piece, e.g. by casting metallic material, by moulding plastics, by blowing vitreous material, by throwing ceramic material, by moulding pulped fibrous material or by deep-drawing operations performed on sheet material
    • B65D1/02Bottles or similar containers with necks or like restricted apertures, designed for pouring contents
    • B65D1/0223Bottles or similar containers with necks or like restricted apertures, designed for pouring contents characterised by shape
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D2501/00Containers having bodies formed in one piece
    • B65D2501/0009Bottles or similar containers with necks or like restricted apertures designed for pouring contents
    • B65D2501/0018Ribs
    • B65D2501/0036Hollow circonferential ribs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2299/00Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/11Orthomyxoviridae, e.g. influenza virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mechanical Engineering (AREA)
  • Ceramic Engineering (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Containers Having Bodies Formed In One Piece (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES08838119.9T 2007-10-09 2008-10-09 Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN Active ES2454773T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US99839807P 2007-10-09 2007-10-09
US998398P 2007-10-09
US7079208P 2008-03-25 2008-03-25
US70792P 2008-03-25
US12345608P 2008-04-08 2008-04-08
US123456P 2008-04-08
PCT/EP2008/008543 WO2009046983A1 (en) 2007-10-09 2008-10-09 Soluble fragments of influenza virus pb2 protein capable of binding rna-cap

Publications (1)

Publication Number Publication Date
ES2454773T3 true ES2454773T3 (es) 2014-04-11

Family

ID=40364724

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08838119.9T Active ES2454773T3 (es) 2007-10-09 2008-10-09 Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN

Country Status (11)

Country Link
US (1) US9045248B2 (https=)
EP (2) EP2197901B1 (https=)
JP (3) JP5725861B2 (https=)
KR (1) KR101672554B1 (https=)
CN (1) CN101970465B (https=)
AU (1) AU2008309939B2 (https=)
CA (1) CA2701362A1 (https=)
ES (1) ES2454773T3 (https=)
IL (3) IL204891A (https=)
SG (1) SG185289A1 (https=)
WO (1) WO2009046983A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2197901B1 (en) * 2007-10-09 2013-12-11 European Molecular Biology Laboratory (Embl) Soluble fragments of influenza virus pb2 protein capable of binding rna-cap
LT3141252T (lt) 2009-06-17 2018-11-12 Vertex Pharmaceuticals Inc. Gripo virusų replikacijos inhibitoriai
KR20130075726A (ko) * 2010-03-16 2013-07-05 유럽피안 몰레큘러 바이올로지 래보러토리 유행성 인플루엔자 바이러스 a 2009 h1n1로부터의 rna 의존성 rna 폴리머라제의 pa 아단위의 단편 및 이의 용도
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
HK1209140A1 (en) * 2012-07-19 2016-03-24 Zoetis Services Llc Bovine influenza c virus compositions
JP6618901B2 (ja) 2013-11-13 2019-12-11 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated インフルエンザウイルスの複製の阻害剤を調製する方法
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
CN105018441A (zh) * 2014-04-22 2015-11-04 中国科学院生物物理研究所 流感病毒rna聚合酶结晶的方法
CN105002149B (zh) * 2014-04-22 2018-04-06 中国科学院生物物理研究所 流感病毒rna聚合酶纯化或结晶的方法
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
CN107286044B (zh) 2016-04-13 2021-07-13 香港神农有限公司 一种能够抑制流感病毒pb2蛋白与rna帽结合的化合物
CL2018003871A1 (es) * 2018-12-28 2021-01-15 Univ Pontificia Catolica Chile Anticuerpos monoclonales específicos para el antígeno pb2 del virus de la influenza humana (flu), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por flu
WO2020239822A1 (en) 2019-05-27 2020-12-03 The European Molecular Biology Laboratory Nucleic acid construct binding to influenza polymerase pb1 rna synthesis active site
CN113122596B (zh) * 2020-08-20 2023-01-24 深圳市瑞吉生物科技有限公司 一种Cap2结构5′帽子类似物及其制备方法和应用
CN114741315B (zh) * 2022-04-28 2023-06-13 深圳市紫光同创电子有限公司 用例更新方法、装置、电子设备及存储介质
CN116024301B (zh) * 2023-01-16 2025-10-28 北京协同创新研究院 一种rna依赖性rna聚合酶截短体的筛选方法、截短体及应用
WO2025055169A1 (en) * 2023-09-12 2025-03-20 The Chinese University Of Hong Kong A fluorescent probe to measure rna binding and elongation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837852A (en) * 1993-10-14 1998-11-17 Bristol-Myers Squibb Company Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease
EP2197901B1 (en) 2007-10-09 2013-12-11 European Molecular Biology Laboratory (Embl) Soluble fragments of influenza virus pb2 protein capable of binding rna-cap
JP6614523B2 (ja) * 2014-03-28 2019-12-04 地方独立行政法人神奈川県立産業技術総合研究所 インフルエンザウイルスのrna依存性rnaポリメラーゼのpb2サブユニットに対するモノクローナル抗体

Also Published As

Publication number Publication date
IL237903A (en) 2017-10-31
WO2009046983A1 (en) 2009-04-16
SG185289A1 (en) 2012-11-29
IL204891A (en) 2015-04-30
EP2574619A3 (en) 2013-07-31
CA2701362A1 (en) 2009-04-16
JP5937169B2 (ja) 2016-06-22
KR20100074212A (ko) 2010-07-01
JP2011501942A (ja) 2011-01-20
IL222997A0 (en) 2012-12-31
EP2197901A1 (en) 2010-06-23
JP5725861B2 (ja) 2015-05-27
AU2008309939B2 (en) 2013-11-14
IL204891A0 (en) 2010-11-30
JP6309563B2 (ja) 2018-04-11
US9045248B2 (en) 2015-06-02
AU2008309939A1 (en) 2009-04-16
EP2197901B1 (en) 2013-12-11
EP2574619A2 (en) 2013-04-03
KR101672554B1 (ko) 2016-11-03
CN101970465B (zh) 2016-03-16
CN101970465A (zh) 2011-02-09
JP2016176955A (ja) 2016-10-06
JP2015062417A (ja) 2015-04-09
US20110008348A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
ES2454773T3 (es) Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN
ES2545895T3 (es) Proteína de fusión anticancerígena
ES2723774T3 (es) Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
UA103774C2 (uk) Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
BR112018070637A2 (pt) receptores de células t
ES2669303T3 (es) Partículas pseudovíricas quiméricas de influenza que comprenden hemaglutinina
JP2014195454A5 (https=)
MX2017016105A (es) Polinucleotidos y polipeptidos de adenovirus.
PE20081723A1 (es) Vacuna contra el papilomavirus
BR112018070600A2 (pt) receptores de células t
ES2531288T3 (es) Proteína de fusión anticancerígena
ES2691091T3 (es) Vacuna conjugada de péptido antigénico de WT1
ES2531290T3 (es) Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
AR074055A1 (es) Vacuna contra el virus de la enfermedad del caballo africano. vector. peste equina. ahsp vp. polinucleotido aislado. metodo
CO6150187A2 (es) Vacunas para malaria
MY206268A (en) Modified s1 subunit of the coronavirus spike protein
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
AR075932A1 (es) Proteasa coagulante de leche de tipo mejorado derivada del microorganismo rhizomucor sp
WO2015107363A3 (en) Mycobacterial antigen composition
PE20211048A1 (es) Anticuerpos injertados con peptido natriuretico tipo c
BR112018073669A2 (pt) proteína de fusão, composição de uma primeira proteína e uma segunda proteína, complexo de uma primeira proteína e uma segunda proteína, polinucleotídeos que codificam uma proteína de fusão, vetor contendo o polinucleotídeo, célula hospedeira contendo o polinucleotídeo, uso de uma proteína de fusão, composição farmacêutica, e composição farmacêutica para uso
JP2019509717A5 (https=)
CL2009001249A1 (es) Uso de una enzima pectonilitica endopoligalacturonasa para tratar pure de frutas o verduras; procedimiento para tratamiento enzimatico; molecula de adn que codifica un polipeptido con actividad endopoligalacturonasa; polipeptido, vector de expresion y celula huesped que comprende dicha secuencia.
CO2022001782A2 (es) Vacuna contra la peste porcina africana